Therapeutic advancement of chronic lymphocytic leukemia

Journal of Hematology and Oncology

Volumn 5, Issue , 2012, Pages

  Lu, Kang ^a   Wang, Xin ^a,b  

^a SHANDONG PROVINCIAL HOSPITAL AFFILIATED TO SHANDONG UNIVERSITY   (China)

^b SHANDONG UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

Chronic lymphocytic leukemia; Monoclonal antibodies; Treatment

Indexed keywords

ALEMTUZUMAB; BAFETINIB; BENDAMUSTINE; CHLORAMBUCIL; CLADRIBINE; CYCLOPHOSPHAMIDE; DASATINIB; DEXAMETHASONE; DINACICLIB; DOXORUBICIN; FLAVOPIRIDOL; FLUDARABINE; FOSTAMATINIB; IBRUTINIB; IDELALISIB; LENALIDOMIDE; LUMILIXIMAB; METHYLPREDNISOLONE; MITOXANTRONE; NAVITOCLAX; OBINUTUZUMAB; OFATUMUMAB; PENTOSTATIN; POMALIDOMIDE; PREDNISONE; RITUXIMAB; THALIDOMIDE; UNINDEXED DRUG; VINCRISTINE; XL 147;

ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ANEMIA; ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ANTINEOPLASTIC ACTIVITY; BONE MARROW SUPPRESSION; CANCER COMBINATION CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER SURVIVAL; CHROMOSOME 17P; CHROMOSOME DELETION; CHRONIC LYMPHATIC LEUKEMIA; COMPLEMENT DEPENDENT CYTOTOXICITY; CYTOPENIA; DIARRHEA; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; ECCHYMOSIS; FATIGUE; FEBRILE NEUTROPENIA; GENE DELETION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; HYPERGLYCEMIA; HYPERTENSION; INFECTION; LEUKEMIA RELAPSE; LEUKEMIA REMISSION; LOW DRUG DOSE; LYMPHADENOPATHY; LYMPHOCYTOMA; LYMPHOMA; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; OVERALL SURVIVAL; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); RANDOMIZED CONTROLLED TRIAL (TOPIC); REDUCED INTENSITY CONDITIONING; REFRACTORY CHRONIC LYMPHATIC LEUKEMIA; REVIEW; THROMBOCYTOPENIA; TREATMENT RESPONSE;

AGED; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COMBINED MODALITY THERAPY; FEMALE; HUMANS; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; MALE; MIDDLE AGED;

EID: 84866174279     PISSN: None     EISSN: 17568722     Source Type: Journal    
DOI: 10.1186/1756-8722-5-55     Document Type: Review

References (111)

1. Chronic lymphocytic leukaemia. Dighiero G, Hamblin TJ, Lancet 2008 371 1017 1029 10.1016/S0140-6736(08)60456-0 18358929 (Pubitemid 351389535)
2. From pathogenesis to treatment of chronic lymphocytic leukaemia. Zenz T, Mertens D, Kuppers R, Dohner H, Stilgenbauer S, Nat Rev Cancer 2010 10 37 50 19956173
3. Update in the management of chronic lymphocytic leukemia. Maddocks KJ, Lin TS, J Hematol Oncol 2009 2 29 10.1186/1756-8722-2-29 19619273
4. Fludarabine compared with chlorambucil as primary therapy for chronic lymphocytic leukemia. Rai KR, Peterson BL, Appelbaum FR, Kolitz J, Elias L, Shepherd L, Hines J, Threatte GA, Larson RA, Cheson BD, Schiffer CA, N Engl J Med 2000 343 1750 1757 10.1056/NEJM200012143432402 11114313
5. First-line therapy with fludarabine compared with chlorambucil does not result in a major benefit for elderly patients with advanced chronic lymphocytic leukemia. Eichhorst BF, Busch R, Stilgenbauer S, Stauch M, Bergmann MA, Ritgen M, Kranzhofer N, Rohrberg R, Soling U, Burkhard O, et al. Blood 2009 114 3382 3391 10.1182/blood-2009-02-206185 19605849
6. Bendamustine (Treanda) displays a distinct pattern of cytotoxicity and unique mechanistic features compared with other alkylating agents. Leoni LM, Bailey B, Reifert J, Bendall HH, Zeller RW, Corbeil J, Elliott G, Niemeyer CC, Clin Cancer Res 2008 14 309 317 10.1158/1078-0432.CCR-07-1061 18172283 (Pubitemid 351378007)
7. Phase III randomized study of bendamustine compared with chlorambucil in previously untreated patients with chronic lymphocytic leukemia. Knauf WU, Lissichkov T, Aldaoud A, Liberati A, Loscertales J, Herbrecht R, Juliusson G, Postner G, Gercheva L, Goranov S, et al. J Clin Oncol 2009 27 4378 4384 10.1200/JCO.2008.20.8389 19652068
8. Demographics, Treatment Patterns, Safety, and Real-World Effectiveness in Patients > =70 Years of Age with Chronic Lymphocytic Leukemia Receiving Bendamustine with or without Rituximab. Kolibaba KS, Joshi AD, Sterchele JA, Forsyth M, Alwon E, Beygi H, Kennealey GT, ASH Annual Meeting Abstracts 2011 118 3914
9. Fludarabine plus cyclophosphamide versus fludarabine alone in first-line therapy of younger patients with chronic lymphocytic leukemia. Eichhorst BF, Busch R, Hopfinger G, Pasold R, Hensel M, Steinbrecher C, Siehl S, Jager U, Bergmann M, Stilgenbauer S, et al. Blood 2006 107 885 891 16219797 (Pubitemid 43156283)
10. Assessment of fludarabine plus cyclophosphamide for patients with chronic lymphocytic leukaemia (the LRF CLL4 Trial): a randomised controlled trial. Catovsky D, Richards S, Matutes E, Oscier D, Dyer MJ, Bezares RF, Pettitt AR, Hamblin T, Milligan DW, Child JA, et al. Lancet 2007 370 230 239 10.1016/S0140-6736(07)61125-8 17658394 (Pubitemid 47069536)
11. Phase III trial of fludarabine plus cyclophosphamide compared with fludarabine for patients with previously untreated chronic lymphocytic leukemia: US Intergroup Trial E2997. Flinn IW, Neuberg DS, Grever MR, Dewald GW, Bennett JM, Paietta EM, Hussein MA, Appelbaum FR, Larson RA, Moore DF Jr, Tallman MS, J Clin Oncol 2007 25 793 798 10.1200/JCO.2006.08.0762 17283364 (Pubitemid 350002879)
12. Biologic and Clinical Markers for Outcome after Fludarabine (F) or F Plus Cyclophosphamide (FC)-Comprehensive Analysis of the CLL4 Trial of the GCLLSG. Stilgenbauer S, Eichhorst BF, Busch R, Zenz T, Winkler D, Buhler A, Goede V, Wendtner CM, Lichter P, Emmerich B, et al. ASH Annual Meeting Abstracts 2089 2008 112
13. Comparison of cladribine plus cyclophosphamide with fludarabine plus cyclophosphamide as first-line therapy for chronic lymphocytic leukemia: a phase III randomized study by the Polish Adult Leukemia Group (PALG-CLL3 Study). Robak T, Jamroziak K, Gora-Tybor J, Stella-Holowiecka B, Konopka L, Ceglarek B, Warzocha K, Seferynska I, Piszcz J, Calbecka M, et al. J Clin Oncol 2010 28 1863 1869 10.1200/JCO.2009.25.9630 20212251
14. Cladribine alone and in combination with cyclophosphamide or cyclophosphamide plus mitoxantrone in the treatment of progressive chronic lymphocytic leukemia: report of a prospective, multicenter, randomized trial of the Polish Adult Leukemia Group (PALG CLL2). Robak T, Blonski JZ, Gora-Tybor J, Jamroziak K, Dwilewicz-Trojaczek J, Tomaszewska A, Konopka L, Ceglarek B, Dmoszynska A, Kowal M, et al. Blood 2006 108 473 479 10.1182/blood-2005-12-4828 16551966 (Pubitemid 44061344)
15. Cladribine Alone and in Combination with Cyclophosphamide or Cyclophosphamide and Mitoxantrone in Previously Untreated Patients with Chronic Lymphocytic Leukemia (CLL): Long-Term Follow-up of the the Polish Adult Leukemia Group (PALG CLL2) Study. Robak T, Blonski J, Jamroziak K, Calbecka M, Dwilewicz-Trojaczek J, Boguradzki P, Dmoszynska A, Kowal M, Kloczko J, Piszcz J, et al. ASH Annual Meeting Abstracts 2011 118 3915
16. Randomized phase 2 study of fludarabine with concurrent versus sequential treatment with rituximab in symptomatic, untreated patients with B-cell chronic lymphocytic leukemia: results from Cancer and Leukemia Group B 9712 (CALGB 9712). Byrd JC, Peterson BL, Morrison VA, Park K, Jacobson R, Hoke E, Vardiman JW, Rai K, Schiffer CA, Larson RA, Blood 2003 101 6 14 10.1182/blood-2002-04- 1258 12393429 (Pubitemid 36025880)
17. Chemoimmunotherapy with fludarabine and rituximab produces extended overall survival and progression-free survival in chronic lymphocytic leukemia: long-term follow-up of CALGB study 9712. Woyach JA, Ruppert AS, Heerema NA, Peterson BL, Gribben JG, Morrison VA, Rai KR, Larson RA, Byrd JC, J Clin Oncol 2011 29 1349 1355 10.1200/JCO.2010.31.1811 21321292
18. Combination chemoimmunotherapy with pentostatin, cyclophosphamide, and rituximab shows significant clinical activity with low accompanying toxicity in previously untreated B chronic lymphocytic leukemia. Kay NE, Geyer SM, Call TG, Shanafelt TD, Zent CS, Jelinek DF, Tschumper R, Bone ND, Dewald GW, Lin TS, et al. Blood 2007 109 405 411 10.1182/blood-2006-07-033274 17008537 (Pubitemid 46105933)
19. Pentostatin and rituximab therapy for previously untreated patients with B-cell chronic lymphocytic leukemia. Kay NE, Wu W, Kabat B, LaPlant B, Lin TS, Byrd JC, Jelinek DF, Grever MR, Zent CS, Call TG, Shanafelt TD, Cancer 2010 116 2180 2187 20187101
20. A Phase III trial of fludarabine, cyclophosphamide, and rituximab vs. pentostatin, cyclophosphamide, and rituximab in B-cell chronic lymphocytic leukemia. Reynolds C, Di Bella N, Lyons RM, Hyman W, Richards DA, Robbins GJ, Vellek M, Boehm KA, Zhan F, Asmar L, Invest New Drugs 2012 30 1232 1240 10.1007/s10637-011-9737-y 21922186
21. A Phase I/II Trial of Fludarabine, Bendamustine, and Rituximab (FBR) Chemoimmunotherapy for Previously Treated Patients with CLL. Wierda WG, Balakrishnan K, Ferrajoli A, Kadia T, Cortes JE, O'Brien S, Burger JA, Tambaro FP, Jalayer A, Lerner S, et al. ASH Annual Meeting Abstracts 2011 118 3901
22. Retherapy with Bendamustine-Containing Regimens in Patients with Relapsed/Refractory CLL and Indolent Lymphomas Achieves High Response Rates. Weide R, Feiten S, Friesenhahn V, Heymanns J, Kleboth K, Thomalla J, van Roye C, Koppler H, ASH Annual Meeting Abstracts 2011 118 1615
23. Rituximab Maintenance In Patients with Chronic Lymphocytic Leukemia (CLL) After Upfront Treatment with Rituximab Plus Fludarabine, Cyclophosphamide, and Mitoxantrone (R-FCM): Final Results of a Multicenter Phase II Trial On Behalf of the Spanish CLL Study Group (GELLC). Bosch F, Abrisqueta P, Villamor N, Terol MJ, Gonzalez-Barca E, Gonzalez M, Ferra C, Abella E, Delgado J, Garcia-Marco JA, et al. ASH Annual Meeting Abstracts 2011 118 293
24. Cyclophosphamide, Adriamycin, Vincristine and Prednisone Plus Rituximab (CHOP-R) in Fludarabine (F) Refractory Chronic Lymphocytic Leukemia (CLL) or CLL with Autoimmune Cytopenia (AIC) or Richter's Transformation (RT): Final Analysis of a Phase II Study of the German CLL Study Group. Jenke P, Eichhorst B, Busch R, Anheier N, Duehrsen U, Duerig J, Dreyling MH, Bergmann M, Goebeler ME, Hurtz HJ, et al. ASH Annual Meeting Abstracts 2011 118 2860
25. Alemtuzumab compared with chlorambucil as first-line therapy for chronic lymphocytic leukemia. Hillmen P, Skotnicki AB, Robak T, Jaksic B, Dmoszynska A, Wu J, Sirard C, Mayer J, J Clin Oncol 2007 25 5616 5623 10.1200/JCO.2007.12.9098 17984186
26. An Italian retrospective study on the routine clinical use of low-dose alemtuzumab in relapsed/refractory chronic lymphocytic leukaemia patients. Cortelezzi A, Gritti G, Laurenti L, Cuneo A, Ciolli S, Di Renzo N, Musto P, Mauro FR, Cascavilla N, Falchi L, et al. Br J Haematol 2012 156 481 489 10.1111/j.1365-2141.2011.08965.x 22150204
27. Low dose alemtuzumab in patients with fludarabine-refractory chronic lymphocytic leukemia. Gritti G, Reda G, Maura F, Piciocchi A, Baldini L, Molica S, Neri A, Cortelezzi A, Leuk Lymphoma 2012 53 424 429 10.3109/10428194.2011. 623258 21919823
28. Alemtuzumab Plus Oral Dexamethasone. Followed by Alemtuzumab Maintenance or Allogeneic Transplantation in Ultra High-Risk CLL: Interim Analysis of a Phase II Study of the GCLLSG and fcgcll/MW. Stilgenbauer S, Cymbalista F, Leblond V, Delmer A, Winkler D, Buhler A, Zenz T, Mack S, Busch R, Hinke A, et al. ASH Annual Meeting Abstracts 2011 118 2854
29. Immunochemotherapy with Low-Dose Subcutaneous Alemtuzumab (A) Plus Oral Fludarabine and Cyclophosphamide (FC) Is Safe and Induces More and Deeper Complete Remissions in Untreated Patients with High-Risk Chronic Lymphocytic Leukemia (CLL) Than Chemotherapy with FC Alone. An Early Analysis of the Randomized Phase-III HOVON68 CLL Trial. Geisler CH, van 't Veer MM, van Putten W, Jurlander J, Walewski J, Tjonnfjord G, Itala-Remes M, Kimby E, Kozak T, Polliack A, et al. ASH Annual Meeting Abstracts 2011 118 290
30. Cyclophosphamide, fludarabine, alemtuzumab, and rituximab as salvage therapy for heavily pretreated patients with chronic lymphocytic leukemia. Badoux XC, Keating MJ, Wang X, O'Brien SM, Ferrajoli A, Faderl S, Burger J, Koller C, Lerner S, Kantarjian H, Wierda WG, Blood 2011 118 2085 2093 10.1182/blood-2011-03-341032 21670470
31. Pentostatin, Alemtuzumab, and Low Dose Rituximab Is Effective Therapy for Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL). Zent CS, LaPlant BR, Link BK, Call TG, Shanafelt TD, Bowen DA, Kay N, Weiner GJ, Witzig TE, ASH Annual Meeting Abstracts 2011 118 1790
32. Consolidation Therapy with Subcutaneous Alemtuzumab After Induction Treatment with Oral FC (Fludarabine and Cyclophosphamide) in Previously Untreated Patients Aged 65-70 Years with Advanced Stage Chronic Lymphocytic Leukemia (CLL): Final Results of a Phase II Study From the FCGCLL/WM. Delmer A, Tournilhac O, Lepretre S, Cazin B, Feugier P, Dreyfus B, Mahe B, Leporrier M, Michallet A-S, Jaccard A, et al. ASH Annual Meeting Abstracts 2011 118 3900
33. Eradication of Minimal Residual Disease Using Alemtuzumab Consolidation After High-Dose Methyl-Prednisolone Plus Rituximab (HDMP-R) Is Safe, Effective and Induces Long Term Remission in Chronic Lymphocytic Leukemia. Castro JE, Ariza-Serrano LM, Barajas-Gamboa JS, Diaz-Perez JA, James DF, Ale-Ali A, Kipps TJ, ASH Annual Meeting Abstracts 2011 118 2866
34. Alemtuzumab Consolidation Does Not Improve Outcome for CLL Patients with High Risk Genomic Features on Successive CALGB Trials. Jones JA, Stark A, Zhao W, Lin TS, Rai KR, Marcucci G, Peterson B, Larson RA, Heerema NA, Byrd JC, ASH Annual Meeting Abstracts 2011 118 1791
35. Ofatumumab as single-agent CD20 immunotherapy in fludarabine-refractory chronic lymphocytic leukemia. Wierda WG, Kipps TJ, Mayer J, Stilgenbauer S, Williams CD, Hellmann A, Robak T, Furman RR, Hillmen P, Trneny M, et al. J Clin Oncol 2010 28 1749 1755 10.1200/JCO.2009.25.3187 20194866
36. Final Analysis From the International Trial of Single-Agent Ofatumumab In Patients with Fludarabine-Refractory Chronic Lymphocytic Leukemia. Wierda WG, Kipps TJ, Mayer J, Robak T, Dyer MJ, Furman RR, Hillmen P, Stilgenbauer S, Williams CD, Trneny M, et al. ASH Annual Meeting Abstracts 2010 116 921
37. A Phase II Trial of Ofatumumab for Older Patients and Patients Who Refuse Fludarabine-Based Regimens with Previously Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma. Flinn IW, Harwin WN, Macias-Perez IM, Tucker PS, Waterhouse DM, Papish SW, Jones JA, Hainsworth JD, Byrd JC, ASH Annual Meeting Abstracts 2011 118 3912
38. Chemoimmunotherapy with O-FC in previously untreated patients with chronic lymphocytic leukemia. Wierda WG, Kipps TJ, Durig J, Griskevicius L, Stilgenbauer S, Mayer J, Smolej L, Hess G, Griniute R, Hernandez-Ilizaliturri FJ, et al. Blood 2011 117 6450 6458 10.1182/blood-2010-12-323980 21498674
39. Ofatumumab Based Chemoimmunotherapy (CIT) for Patients with Previously Untreated CLL. Shanafelt TD, Lanasa MC, Zent CS, Leis JF, Call TG, LaPlant BR, Tun H, Bowen DA, Jelinek DF, Hanson CA, Kay N, ASH Annual Meeting Abstracts 2011 118 3898
40. Phase 1 study of lumiliximab with detailed pharmacokinetic and pharmacodynamic measurements in patients with relapsed or refractory chronic lymphocytic leukemia. Byrd JC, O'Brien S, Flinn IW, Kipps TJ, Weiss M, Rai K, Lin TS, Woodworth J, Wynne D, Reid J, et al. Clin Cancer Res 2007 13 4448 4455 10.1158/1078-0432.CCR-06-1463 17671129 (Pubitemid 47219713)
41. Phase 1/2 study of lumiliximab combined with fludarabine, cyclophosphamide, and rituximab in patients with relapsed or refractory chronic lymphocytic leukemia. Byrd JC, Kipps TJ, Flinn IW, Castro J, Lin TS, Wierda W, Heerema N, Woodworth J, Hughes S, Tangri S, et al. Blood 2010 115 489 495 10.1182/blood-2009-08-237727 19843887
42. The clinical application of monoclonal antibodies in chronic lymphocytic leukemia. Jaglowski SM, Alinari L, Lapalombella R, Muthusamy N, Byrd JC, Blood 2010 116 3705 3714 10.1182/blood-2010-04-001230 20610811
43. Novel 3rd Generation Humanized Type II CD20 Antibody with Glycoengineered Fc and Modified Elbow Hinge for Enhanced ADCC and Superior Apoptosis Induction. Umana P, Moessner E, Bruenker P, Unsin G, Puentener U, Suter T, Grau R, Schmidt C, Gerdes C, Nopora A, et al. ASH Annual Meeting Abstracts 2006 108 229
44. Mechanism of action of type II, glycoengineered, anti-CD20 monoclonal antibody GA101 in B-chronic lymphocytic leukemia whole blood assays in comparison with rituximab and alemtuzumab. Bologna L, Gotti E, Manganini M, Rambaldi A, Intermesoli T, Introna M, Golay J, J Immunol 2011 186 3762 3769 10.4049/jimmunol.1000303 21296976
45. Phase I Study of RO5072759 (GA101) in Relapsed/Refractory Chronic Lymphocytic Leukemia. Morschhauser F, Cartron G, Lamy T, Milpied N-J, Thieblemont C, Tilly H, Weisser M, Birkett J, Salles GA, ASH Annual Meeting Abstracts 2009 114 884
46. Pomalidomide plus low-dose dexamethasone in myeloma refractory to both bortezomib and lenalidomide: comparison of 2 dosing strategies in dual-refractory disease. Lacy MQ, Allred JB, Gertz MA, Hayman SR, Short KD, Buadi F, Dispenzieri A, Kumar S, Greipp PR, Lust JA, et al. Blood 2011 118 2970 2975 10.1182/blood-2011-04-348896 21690557
47. Long-term outcome of pomalidomide therapy in myelofibrosis. Begna KH, Pardanani A, Mesa R, Litzow MR, Hogan WJ, Hanson CA, Tefferi A, Am J Hematol 2012 87 66 68 10.1002/ajh.22233 22081489
48. Mechanism of action of lenalidomide in hematological malignancies. Kotla V, Goel S, Nischal S, Heuck C, Vivek K, Das B, Verma A, J Hematol Oncol 2009 2 36 10.1186/1756-8722-2-36 19674465
49. Lenalidomide as initial therapy of elderly patients with chronic lymphocytic leukemia. Badoux XC, Keating MJ, Wen S, Lee BN, Sivina M, Reuben J, Wierda WG, O'Brien SM, Faderl S, Kornblau SM, et al. Blood 2011 118 3489 3498 10.1182/blood-2011-03-339077 21725050
50. Lenalidomide and Rituximab for the Initial Treatment of Patients with Chronic Lymphocytic Leukemia (CLL) A Multicenter Study of the CLL Research Consortium. James DF, Brown JR, Werner L, Wierda WG, Barrientos JC, Castro J, Greaves A, Rassenti LZ, Rai KR, Neuberg D, Kipps TJ, ASH Annual Meeting Abstracts 2011 118 291
51. Final Analysis of a Phase 2 Study of Lenalidomide and Rituximab in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL). Badoux XC, Keating MJ, O'Brien S, Wierda WG, Faderl S, Estrov Z, Pasia M, Lerner S, Sargent RL, Kantarjian HM, Ferrajoli A, ASH Annual Meeting Abstracts 2011 118 980
52. Combination Therapy with Ofatumumab and Lenalidomide in Patients with Relapsed Chronic Lymphocytic Leukemia (CLL): Results of a Phase II Trial. Ferrajoli A, O'Brien S, Wierda WG, Faderl S, Badoux X, Estrov Z, Schlette E, Smith SC, Ayala AB, Falchi L, et al. ASH Annual Meeting Abstracts 2011 118 1788
53. Lenalidomide Consolidation Appears to Prolong Time to Retreatment After First-Line Chemoimmunotherapy for Patients with Previously Untreated CLL. Shanafelt TD, Tun H, Hanson CA, Zent CS, Leis JF, Call TG, LaPlant BR, Bowen D, Pavey ES, Jelinek DF, Kay N, ASH Annual Meeting Abstracts 2011 118 3899
54. Initial Experience with Lenalidomide As Consolidation Treatment in Patients with Chronic Lymphocytic Leukemia and Residual Disease After Chemotherapy. Pozadzides JV, Keating MJ, Wierda WG, O'Brien S, Burger JA, Jorgensen JL, Calin S, Wang S, Lerner S, Ferrajoli A, ASH Annual Meeting Abstracts 2011 118 3907
55. Methylprednisolone in advanced chronic lymphocytic leukaemia: rationale for, and effectiveness of treatment suggested by DiSC assay. Bosanquet AG, McCann SR, Crotty GM, Mills MJ, Catovsky D, Acta Haematol 1995 93 73 79 10.1159/000204115 7543720
56. High dose methyl prednisolone in refractory chronic lymphocytic leukaemia. Thornton PD, Hamblin M, Treleaven JG, Matutes E, Lakhani AK, Catovsky D, Leuk Lymphoma 1999 34 167 170 10350345 (Pubitemid 29248672)
57. High dose methylprednisolone can induce remissions in CLL patients with p53 abnormalities. Thornton PD, Matutes E, Bosanquet AG, Lakhani AK, Grech H, Ropner JE, Joshi R, Mackie PH, Douglas ID, Bowcock SJ, Catovsky D, Ann Hematol 2003 82 759 765 10.1007/s00277-003-0710-5 14551737 (Pubitemid 38008843)
58. Rituximab in combination with high-dose methylprednisolone for the treatment of fludarabine refractory high-risk chronic lymphocytic leukemia. Castro JE, Sandoval-Sus JD, Bole J, Rassenti L, Kipps TJ, Leukemia 2008 22 2048 2053 10.1038/leu.2008.214 18754025
59. Rituximab in combination with high-dose methylprednisolone for the treatment of chronic lymphocytic leukemia. Castro JE, James DF, Sandoval-Sus JD, Jain S, Bole J, Rassenti L, Kipps TJ, Leukemia 2009 23 1779 1789 10.1038/leu.2009.133 19693094
60. Methylprednisolone-rituximab is an effective salvage therapy for patients with relapsed chronic lymphocytic leukemia including those with unfavorable cytogenetic features. Bowen DA, Call TG, Jenkins GD, Zent CS, Schwager SM, Van Dyke DL, Jelinek DF, Kay NE, Shanafelt TD, Leuk Lymphoma 2007 48 2412 2417 10.1080/10428190701724801 18067017 (Pubitemid 350253473)
61. Dose-dense high-dose methylprednisolone and rituximab in the treatment of relapsed or refractory high-risk chronic lymphocytic leukemia. Pileckyte R, Jurgutis M, Valceckiene V, Stoskus M, Gineikiene E, Sejoniene J, Degulys A, Zvirblis T, Griskevicius L, Leuk Lymphoma 2011 52 1055 1065 10.3109/10428194. 2011.562572 21599591
62. Ofatumumab and High-Dose Methylprednisolone Is An Effective Salvage Treatment for Heavily Pretreated, Unfit or Refractory Patients with Chronic Lymphocytic Leukemia: Single Institution Experience. Castro JE, Barajas-Gamboa JS, Melo-Cardenas J, Paz RN, Bernal-Corzo C, Ale-Ali A, James DF, Kipps TJ, ASH Annual Meeting Abstracts 2010 116 4638
63. Phase II study of flavopiridol in relapsed chronic lymphocytic leukemia demonstrating high response rates in genetically high-risk disease. Lin TS, Ruppert AS, Johnson AJ, Fischer B, Heerema NA, Andritsos LA, Blum KA, Flynn JM, Jones JA, Hu W, et al. J Clin Oncol 2009 27 6012 6018 10.1200/JCO.2009.22.6944 19826119
64. Interim Analysis of EFC6663, a Multicenter Phase 2 Study of Alvocidib (flavopiridol), Demonstrates Clinical Responses Among Patients with Fludarabine Refractory CLL. Lanasa MC, Andritsos L, Brown JR, Gabrilove J, Caligaris-Cappio F, Larson R, Kipps TJ, Leblond V, Milligan D, Janssens A, et al. ASH Annual Meeting Abstracts 2010 116 58
65. Response, Progression-Free Survival, and Overall Survival of Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) Treated with Flavopiridol: Impact of Poor Risk Cytogenetic Abnormalities. Woyach JA, Ruppert AS, Blum KA, Jones JA, Flynn JM, Johnson AJ, Grever MR, Byrd JC, Heerema NA, ASH Annual Meeting Abstracts 2010 116 2456
66. Flavopiridol treatment of patients aged 70 or older with refractory or relapsed chronic lymphocytic leukemia is a feasible and active therapeutic approach. Stephens DM, Ruppert AS, Blum K, Jones J, Flynn JM, Johnson AJ, Ji J, Phelps MA, Grever MR, Byrd JC, Haematologica 2012 97 423 427 10.3324/haematol.2011.047324 22271900
67. Activity of Combined Flavopiridol and Lenalidomide in Patients with Cytogenetically High Risk Chronic Lymphocytic Leukemia (CLL): Updated Results of a Phase I Trial. Blum KA, Wei L, Jones JA, Andritsos LA, Flynn JM, Heerema NA, Yang X, Rozewski D, Phelps M, Johnson AJ, et al. ASH Annual Meeting Abstracts 2011 118 3910
68. Update on the Phase I Study of the Cyclin Dependent Kinase Inhibitor Dinaciclib (SCH 727965) In Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL): Confirmation of Clinical Activity and Feasibility of Long-Term Administration. Flynn JM, Jones JA, Andritsos L, Blum KA, Johnson AJ, Hessler J, Wiley E, Poon J, Small K, Statkevich P, et al. ASH Annual Meeting Abstracts 2010 116 1396
69. An Ongoing Phase 1/2a Study of ABT-263; Pharmacokinetics (PK), Safety and Anti-Tumor Activity in Patients (pts) with Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL). Roberts AW, Seymour JF, Brown JR, Wierda WG, Kipps TJ, Carney D, Xiong H, Cui Y, Busman T, Enschede S, et al. ASH Annual Meeting Abstracts 2009 114 883
70. Substantial susceptibility of chronic lymphocytic leukemia to BCL2 inhibition: results of a phase I study of navitoclax in patients with relapsed or refractory disease. Roberts AW, Seymour JF, Brown JR, Wierda WG, Kipps TJ, Khaw SL, Carney DA, He SZ, Huang DC, Xiong H, et al. J Clin Oncol 2012 30 488 496 10.1200/JCO.2011.34.7898 22184378
71. Navitoclax (ABT-263) Plus Fludarabine/Cyclophosphamide/Rituximab (FCR) or Bendamustine/Rituximab (BR): A Phase 1 Study in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL). Kipps TJ, Swinnen LJ, Wierda WG, Jones JA, Coutre SE, Smith MR, Yang J, Cui Y, Busman T, Enschede S, Humerickhouse R, ASH Annual Meeting Abstracts 2011 118 3904
72. 5-year survival in patients with relapsed or refractory chronic lymphocytic leukemia in a randomized, phase III trial of fludarabine plus cyclophosphamide with or without oblimersen. O'Brien S, Moore JO, Boyd TE, Larratt LM, Skotnicki AB, Koziner B, Chanan-Khan AA, Seymour JF, Gribben J, Itri LM, Rai KR, J Clin Oncol 2009 27 5208 5212 10.1200/JCO.2009.22.5748 19738118
73. AT-101 induces apoptosis in CLL B cells and overcomes stromal cell-mediated Mcl-1 induction and drug resistance. Balakrishnan K, Burger JA, Wierda WG, Gandhi V, Blood 2009 113 149 153 10.1182/blood-2008-02-138560 18836097
74. Phase I study of obatoclax mesylate (GX15-070), a small molecule pan-Bcl-2 family antagonist, in patients with advanced chronic lymphocytic leukemia. O'Brien SM, Claxton DF, Crump M, Faderl S, Kipps T, Keating MJ, Viallet J, Cheson BD, Blood 2009 113 299 305 18931344
75. The novel antisense Bcl-2 inhibitor SPC2996 causes rapid leukemic cell clearance and immune activation in chronic lymphocytic leukemia. Durig J, Duhrsen U, Klein-Hitpass L, Worm J, Hansen JB, Orum H, Wissenbach M, Leukemia 2011 25 638 647 10.1038/leu.2010.322 21358717
76. The phosphoinositide 3'-kinase delta inhibitor, CAL-101, inhibits B-cell receptor signaling and chemokine networks in chronic lymphocytic leukemia. Hoellenriegel J, Meadows SA, Sivina M, Wierda WG, Kantarjian H, Keating MJ, Giese N, O'Brien S, Yu A, Miller LL, et al. Blood 2011 118 3603 3612 10.1182/blood-2011-05-352492 21803855
77. CAL-101, An Isoform-Selective Inhibitor of Phosphatidylinositol 3-Kinase P110{delta}, Demonstrates Clinical Activity and Pharmacodynamic Effects In Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia. Furman RR, Byrd JC, Brown JR, Coutre SE, Benson DM, Wagner-Johnston ND, Flinn IW, Kahl BS, Spurgeon SE, Lannutti B, et al. ASH Annual Meeting Abstracts 2010 116 55
78. A Phase 1 Study of the Selective Phosphatidylinositol 3-Kinase-Delta (PI3K{delta}) Inhibitor, CAL-101 (GS-1101), in Combination with Rituximab and/or Bendamustine in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL). Sharman J, de Vos S, Leonard JP, Furman RR, Coutre SE, Flinn IW, Schreeder MT, Barrientos JC, Wagner-Johnston ND, Boyd T, et al. ASH Annual Meeting Abstracts 2011 118 1787
79. Phase I Trial of SAR245408 (S08), a Pan-Phosphatidylinositol 3 Kinase (PI3K) Inhibitor, in Patients with Chronic Lymphocytic Leukemia (CLL) and Lymphoma. Brown JR, Davids MS, Rodon J, Abrisqueta P, DeCillis AP, Rockich K, Egile C, Kelly A, Xu Y, Lager J, Awan FT, ASH Annual Meeting Abstracts 2011 118 2683
80. The clinically active BTK inhibitor PCI-32765 targets B-cell receptor- and chemokine-controlled adhesion and migration in chronic lymphocytic leukemia. de Rooij MF, Kuil A, Geest CR, Eldering E, Chang BY, Buggy JJ, Pals ST, Spaargaren M, Blood 2012 119 2590 2594 10.1182/blood-2011-11-390989 22279054
81. Activity and tolerability of the Bruton's tyrosine kinase (Btk) inhibitor PCI-32765 in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL): Interim results of a phase Ib/II study. Byrd JC, Blum KA, Burger JA, Coutre SE, Sharman JP, Furman RR, Flinn IW, Grant BW, Richards DA, Zhao W, et al. ASCO Meeting Abstracts 2011 29 6508
82. The Bruton's Tyrosine Kinase (BTK) Inhibitor PCI-32765 Induces Durable Responses in Relapsed or Refractory (R/R) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL): Follow-up of a Phase Ib/II Study. O'Brien S, Burger JA, Blum KA, Furman RR, Coutre SE, Sharman J, Flinn IW, Grant B, Heerema NA, Johnson AJ, et al. ASH Annual Meeting Abstracts 2011 118 983
83. Inhibition of Syk with fostamatinib disodium has significant clinical activity in non-Hodgkin lymphoma and chronic lymphocytic leukemia. Friedberg JW, Sharman J, Sweetenham J, Johnston PB, Vose JM, Lacasce A, Schaefer-Cutillo J, De Vos S, Sinha R, Leonard JP, et al. Blood 2010 115 2578 2585 10.1182/blood-2009-08-236471 19965662
84. B-cell antigen receptor signaling enhances chronic lymphocytic leukemia cell migration and survival: specific targeting with a novel spleen tyrosine kinase inhibitor, R406. Quiroga MP, Balakrishnan K, Kurtova AV, Sivina M, Keating MJ, Wierda WG, Gandhi V, Burger JA, Blood 2009 114 1029 1037 10.1182/blood-2009-03-212837 19491390
85. Selective, novel spleen tyrosine kinase (Syk) inhibitors suppress chronic lymphocytic leukemia B-cell activation and migration. Hoellenriegel J, Coffey GP, Sinha U, Pandey A, Sivina M, Ferrajoli A, Ravandi F, Wierda WG, O'Brien S, Keating MJ, Burger JA, Leukemia 2012 26 1576 1583 10.1038/leu.2012.24 22362000
86. Phase II study of dasatinib in relapsed or refractory chronic lymphocytic leukemia. Amrein PC, Attar EC, Takvorian T, Hochberg EP, Ballen KK, Leahy KM, Fisher DC, Lacasce AS, Jacobsen ED, Armand P, et al. Clin Cancer Res 2011 17 2977 2986 10.1158/1078-0432.CCR-10-2879 21402714
87. Phase II Study of Dasatinib In Patients with Relapsed Chronic Lymphocytic Leukemia. Al-Ameri AM, Badoux X, Ferrajoli A, Wierda WG, Fayad L, Estrov Z, Bickel S, Keating MJ, O'Brien S, ASH Annual Meeting Abstracts 2010 116 4488
88. A Pilot Phase II Study of the Lyn Kinase Inhibitor Bafetinib in Patients with Relapsed or Refractory B Cell Chronic Lymphocytic Leukemia. Kadia T, Delioukina ML, Kantarjian HM, Keating MJ, Wierda WG, Burger JA, Wieland S, Levitt D, ASH Annual Meeting Abstracts 2011 118 2858
89. Autologous hematopoietic stem cell transplantation in chronic lymphocytic leukemia: results of European intergroup randomized trial comparing autografting versus observation. Michallet M, Dreger P, Sutton L, Brand R, Richards S, van Os M, Sobh M, Choquet S, Corront B, Dearden C, et al. Blood 2011 117 1516 1521 10.1182/blood-2010-09-308775 21106985
90. Early autologous stem cell transplantation for chronic lymphocytic leukemia: long-term follow-up of the German CLL Study Group CLL3 trial. Dreger P, Dohner H, McClanahan F, Busch R, Ritgen M, Greinix H, Fink AM, Knauf W, Stadler M, Pfreundschuh M, et al. Blood 2012 119 4851 4859 10.1182/blood-2011- 09-378505 22490331
91. Allogeneic transplant with reduced intensity conditioning regimens may overcome the poor prognosis of B-cell chronic lymphocytic leukemia with unmutated immunoglobulin variable heavy-chain gene and chromosomal abnormalities (11q- and 17p-). Caballero D, Garcia-Marco JA, Martino R, Mateos V, Ribera JM, Sarra J, Leon A, Sanz G, de la Serna J, Cabrera R, et al. Clin Cancer Res 2005 11 7757 7763 10.1158/1078-0432.CCR-05-0941 16278397 (Pubitemid 41611619)
92. Allogeneic stem-cell transplantation may overcome the adverse prognosis of unmutated VH gene in patients with chronic lymphocytic leukemia. Moreno C, Villamor N, Colomer D, Esteve J, Martino R, Nomdedeu J, Bosch F, Lopez-Guillermo A, Campo E, Sierra J, Montserrat E, J Clin Oncol 2005 23 3433 3438 10.1200/JCO.2005.04.531 15809449
93. Unrelated donor marrow transplantation for B-cell chronic lymphocytic leukemia after using myeloablative conditioning: results from the Center for International Blood and Marrow Transplant research. Pavletic SZ, Khouri IF, Haagenson M, King RJ, Bierman PJ, Bishop MR, Carston M, Giralt S, Molina A, Copelan EA, et al. J Clin Oncol 2005 23 5788 5794 10.1200/JCO.2005.03.962 16043827
94. Outcome of allogeneic stem cell transplantation for B cell chronic lymphocytic leukemia. Pavletic ZS, Arrowsmith ER, Bierman PJ, Goodman SA, Vose JM, Tarantolo SR, Stein RS, Bociek G, Greer JP, Wu CD, et al. Bone Marrow Transplant 2000 25 717 722 10.1038/sj.bmt.1702237 10745256 (Pubitemid 30189511)
95. Allotransplantation for chronic lymphocytic leukemia. Dreger P, Hematology / the Education Program of the American Society of Hematology American Society of Hematology Education Program 2009 1 602 609
96. Allogeneic hematopoietic cell transplantation for chronic lymphocytic leukemia: ready for prime time? Delgado J, Milligan DW, Dreger P, Blood 2009 114 2581 2588 10.1182/blood-2009-05-206821 19641189
97. Hematopoietic stem cell allografting for chronic lymphocytic leukemia: a focus on reduced-intensity conditioning regimens. Kharfan-Dabaja MA, Bazarbachi A, Cancer control: journal of the Moffitt Cancer Center 2012 19 68 75
98. Feasibility Analysis of Nonmyeloabltive Allogeneic Stem Cell Transplantation (NST) in Patients with Chronic Lymphocytic Leukemia (CLL) and 17p- Deletion. Hsu Y, Saliba RM, Okoroji G-J, o'Brien S, Ferrajoli A, Abruzzo LV, Champlin R, Keating MJ, Khouri IF, ASH Annual Meeting Abstracts 2011 118 4123
99. Veltuzumab, an anti-CD20 mAb for the treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia and immune thrombocytopenic purpura. Milani C, Castillo J, Curr Opin Mol Ther 2009 11 200 207 19330725
100. Results of a phase 1 study of AME-133v (LY2469298), an Fc-engineered humanized monoclonal anti-CD20 antibody, in FcgammaRIIIa-genotyped patients with previously treated follicular lymphoma. Forero-Torres A, de Vos S, Pohlman BL,
101. The anti-CD20 mAb LFB-R603 interrupts the dysregulated NF-kappaB/Snail/RKIP/PTEN resistance loop in B-NHL cells: role in sensitization to TRAIL apoptosis. Baritaki S, Militello L, Malaponte G, Spandidos DA, Salcedo M, Bonavida B, Int J Oncol 2011 38 1683 1694 21455568
102. CD20-directed small modular immunopharmaceutical, TRU-015, depletes normal and malignant B cells. Hayden-Ledbetter MS, Cerveny CG, Espling E, Brady WA, Grosmaire LS, Tan P, Bader R, Slater S, Nilsson CA, Barone DS, et al. Clin Cancer Res 2009 15 2739 2746 10.1158/1078-0432.CCR-08-1694 19351771
103. TRU-016, a humanized anti-CD37 IgG fusion protein for the potential treatment of B-cell malignancies. Robak T, Robak P, Smolewski P, Curr Opin Investig Drugs 2009 10 1383 1390 19943209
104. A phase I study of dacetuzumab (SGN-40, a humanized anti-CD40 monoclonal antibody) in patients with chronic lymphocytic leukemia. Furman RR, Forero-Torres A, Shustov A, Drachman JG, Leuk Lymphoma 2010 51 228 235 10.3109/10428190903440946 20038235
105. Phase I study of the anti-CD40 humanized monoclonal antibody lucatumumab (HCD122) in relapsed chronic lymphocytic leukemia. Byrd JC, Kipps TJ, Flinn IW, Cooper M, Odenike O, Bendiske J, Rediske J, Bilic S, Dey J, Baeck J, O'Brien S, Leuk Lymphoma 2012 in press
106. The Hsp90 inhibitor SNX-7081 synergizes with and restores sensitivity to fludarabine in chronic lymphocytic leukemia cells with lesions in the TP53 pathway: a potential treatment strategy for fludarabine refractory disease. Best OG, Che Y, Singh N, Forsyth C, Christopherson RI, Mulligan SP, Leuk Lymphoma 2012 53 1367 1375 10.3109/10428194.2011.647310 22149137
107. 17-DMAG targets the nuclear factor-kappaB family of proteins to induce apoptosis in chronic lymphocytic leukemia: clinical implications of HSP90 inhibition. Hertlein E, Wagner AJ, Jones J, Lin TS, Maddocks KJ, Towns WH 3rd, Goettl VM, Zhang X, Jarjoura D, Raymond CA, et al. Blood 2010 116 45 53 10.1182/blood-2010-01-263756 20351313
108. Novel histone deacetylase inhibitors in clinical trials as anti-cancer agents. Tan J, Cang S, Ma Y, Petrillo RL, Liu D, J Hematol Oncol 2010 3 5 10.1186/1756-8722-3-5 20132536
109. Phase II study of cenersen, an antisense inhibitor of p53, in combination with fludarabine, cyclophosphamide and rituximab for high-risk chronic lymphocytic leukemia. Lanasa MC, Davis PH, Datto M, Li Z, Gockerman JP, Moore JO, Decastro CM, Friedman DR, Diehl LF, Rehder C, et al. Leuk Lymphoma 2012 53 218 224 10.3109/10428194.2011.610012 21827374
110. Novel targeted therapeutics: inhibitors of MDM2. ALK and PARP. Yuan Y, Liao YM, Hsueh CT, Mirshahidi HR, Journal of hematology & oncology 2011 4 16 10.1186/1756-8722-4-16 22983591
111. A pilot trial of the mTOR (mammalian target of rapamycin) inhibitor RAD001 in patients with advanced B-CLL. Decker T, Sandherr M, Goetze K, Oelsner M, Ringshausen I, Peschel C, Ann Hematol 2009 88 221 227 10.1007/s00277-008- 0582-9 18704419